AQP1 and endometrial cancer: Combining ion channel inhibitors of AQP1 with hormonal therapy in patients with endometrial cancer could address resistance to hormonal treatments, and could also help reduce the intensity of regular cancer treatments needed, sparing patients from the associated side effects.